Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial

Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial

Introduction: Sequential therapy with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) is effective in some patients with metastatic renal cell carcinoma (mRCC) progressed from or were intolerant to a prior TKIs. Anlotinib is a multi-kinase inhibitor targeting VEGF...

Full description

Bibliographic Details
Main Authors: Jianhui Ma, Yan Song, Jianzhong Shou, Yuxian Bai, Hanzhong Li, Xiaodong Xie, Hong Luo, Xiubao Ren, Jiyan Liu, Dingwei Ye, Xianzhong Bai, Cheng Fu, Shukui Qin, Jinwan Wang, Ai-Ping Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Oncology
Subjects:
anlotinib
metastatic renal cell carcinoma
tyrosine kinase inhibitor
second-line
FGFR
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00664/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00664/full

Similar Items